Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Seagen filed SEC Schedule 14A outlining Pfizer $43 Bln M&A

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Jul 27, 2023 3:42pm

187 Views

Post# 35560287

RE:RE:RE:RE:RE:RE:RE:RE:Seagen filed SEC Schedule 14A outlining Pfizer $43 Bln M&A

Replying to Jimsenior, if ONCY and pela proves to have such widespread reach and unique benefits in combos, then the future BP owner may be forced by the FTC to make it available through license to its competitors. It would then be like a common carrrier, or common adjuvant aid, similar to how electric utilities must license their line capacity to their competitors to avoid being anti-competitive./

The pela public utility!

<< Previous

Bullboard Posts

Next >>

B2Gold stock buckles under news of labour strike in Mali